Abstract
Batterham et al. report that the gut peptide hormone PYY3-36 decreases food intake and body-weight gain in rodents, a discovery that has been heralded as potentially offering a new therapy for obesity. However, we have been unable to replicate their results. Although the reasons for this discrepancy remain undetermined, an effective anti-obesity drug ultimately must produce its effects across a range of situations. The fact that the findings of Batterham et al. cannot easily be replicated calls into question the potential value of an anti-obesity approach that is based on administration of PYY3-36.
MeSH terms
-
Animals
-
Animals, Inbred Strains
-
Appetite / drug effects
-
Appetite / physiology
-
Appetite Depressants / pharmacology*
-
Appetite Depressants / therapeutic use
-
Appetite Regulation / drug effects*
-
Behavior, Animal / drug effects
-
Body Weight / drug effects
-
Environment
-
Feeding Behavior / drug effects*
-
Humans
-
Meta-Analysis as Topic
-
Mice
-
Obesity / drug therapy
-
Peptide Fragments
-
Peptide YY / administration & dosage
-
Peptide YY / blood
-
Peptide YY / pharmacology*
-
Peptide YY / therapeutic use
-
Rats
-
Reproducibility of Results
-
Stress, Physiological / complications
-
Stress, Physiological / physiopathology
Substances
-
Appetite Depressants
-
Peptide Fragments
-
Peptide YY
-
peptide YY (3-36)